A new batch of pain therapeutics are advancing through clinical trials and investors in companies focused on pain are likely to benefit from FDA submissions and product news over the next six months. This special issue of Neurotech Insights, focused on pain, covers current and next generation pain treatments from COX Inhibitors to cannabinoids and psychological intervention to neurostimulation.
